European Journal of Cancer · 2012 · 115 citations · 16 references
MedicineOncologyPharmacologyMetastasisMolecular OncologyNeoplasiaMalignant NeoplasmsMelanocytic TumorsMelanoma PharmacotherapyMetastatic Disease TreatmentTargeted Cancer TherapyBraf V600 MutationsBraf V600e MutationMelanoma ProgressionMetastatic Melanoma TreatmentOncogenic Braf Signaling
16
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations
Medicine, Oncology, Pharmacology +17
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text
Medicine, Oncology, Pharmacology +16